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Summary 
An increased  ratio of T  helper type 2  (Th2)-  vs Thl-like calls contributes to  the immune 
dysregulation in allergic disease situations and in many chronic infections, including AIDS. Th2- 
type immune responses are characterized by Th cells that produce increased levels ofinterleukin-4 
(IL-4) and decreased levels of interferon 3/(IFN-7). The induction of either a Thl- or a Th2-1ike 
phenotype may be critically controlled by the antigen-presenting ceUs and their cytokines, e.g., 
IFN-ce. In this study we have determined the frequencies of potential IL-4- and/or IFN-7-producing 
T cells in the peripheral blood of randomly selected healthy individuals,  and analyzed whether 
IFN-ce controls IL-4 and/or IFN-7 production. Purified CD4 § or CD8 + T cells were stimulated 
for 24 h via the T cell receptor/CD3 complex in the presence or absence of IFN-cx, and single 
IL-4- and IFN-7-secreting cells were detected in enzyme-linked immunospot assays. In the absence 
of IFN-c~, CD4 cells produced IFN-7 at frequencies of 1:50-300, and produced IL-4 at frequencies 
of 1:110-<1:100,000.  Addition of IFN-ol during the activation of CD4 cells increased the levels 
of IFN-7 mRNA. As a consequence, the numbers of IFN-7-producing CD4 cells and the amounts 
of secreted IFN-7 increased 10-fold. In contrast, IFN-c~ did not increase the frequency of IL-4- 
secreting CD4 cells. In the absence of IFN-o~, addition of exogenous IL-4 to cultures of CD4 
cells suppressed IFN-7 secretion by 70%. However, in the presence of IFN-ce, IL-4 did not display 
any suppressive effect. Compared with CD4 cells, CD8 cells produced IFN-7 more frequently 
(1:5-10) but IL-4 less frequently (1:5,300 to <1:100,000).  IFN-c~ did not display any effect on 
the frequency of either IFN-7 or IL-4 production by CD8 cells. Taken together the resuhs indicate 
that IFN-cx increases the frequency of IFN-7-secreting CD4 Th cells and antagonizes the suppressive 
effect of IL-4 on IFN-'y production. As a consequence, IFN-oc may favor the induction and 
maintenance of Thl-like cells and thereby counteract Th2-driven allergic immune responses. 
I 
FN-c~ has a wide range of immunomodulatory activities 
(1, 2). The cytokine has been used successfully for the treat- 
ment of viral infections (3-8), including AIDS (7, 8), and 
also displays beneficial effects in several tumor-associated dis- 
eases (9-12),  and in allergic disorders (13, 14). Despite the 
broad indication range for IFN-o~, the detailed mechanism 
of IFN-ol action in vivo as well as its target ceils have not 
been well defined. It has been found that IFN-c~ modulates 
the immunoglobulin isotype selection process, since it sup- 
presses IgE production in an isotype-specific fashion in vitro 
(15) as well as in vivo (13, 16, 17). A direct effect of IFN-o~ 
on B  calls is unlikely,  since IFN-ce  does not  inhibit IgE 
switching of human B calls upon physical interaction with 
preactivated helper calls in the absence of IFN-7 and in the 
presence of exogenously added IL-2  and  IL-4  (18).  It  is 
tempting to speculate that IFN-c~ suppresses IgE production 
by modulating lymphokine expression by Th cells, since the 
immunoglobulin switch of B cells to IgE is induced by IL-4 
(19-22),  and antagonized by IFN-7 (15, 21, 22).  This in- 
terpretation is supported by the finding that, in mice stimu- 
lated with a foreign anti-IgD antibody, IFN-cr reduced the 
IgE and IgG1 response as well as the levels of splenic IL-4 
mRNA, but increased the levels of splenic IFN-7 mRNA 
(16). However,  since the mRNA levels were quantified in 
unfractionated spleen cells, it was not clear whether IFN-ol 
acts on the level oflL-4 or IFN-7 gene expression, or whether 
the decreased levels of IL-4 mRNA reflect a selective accumu- 
lation of IFN-7-producing cells in the spleen. With human 
cells it has been found that addition of IFN-o~ to cultures 
of PBMC before long-term T cell cloning favored the devel- 
opment of T  cell clones  that express a Thl, rather than a 
Th2, cytokine profile (23).  Thl cells mainly release IFN-7 
and IL-2, while Th2 cells release IL-4, IL-5, and IL-10, the 
lymphokines involved  in the control of allergic  responses 
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have  not been clearly defined in either human or murine 
systems. 
In this report we analyzed the effect of IFN-ot on the ex- 
pression of IL-4 and IFN-'y by freshly isolated human CD4 + 
Th cells and CD8 + cytotoxic-suppressive T  cells. Since the 
secretion of IL-4 by T cells is generally low, and IL-4 is barely 
detectable in the culture supernatants due to rapid consump- 
tion of the lymphokine by the growing cells, we have estab- 
hshed enzyme-linked immunospot (ELISPOT)  1 assays to de- 
tect single IL-4- and IFN-3,-secreting cells within 24 h of 
culture. Several reports from us and others have attested to 
the versatility of this methodological principle for enumer- 
ating cells that secrete antibody or lymphokines (30-35). We 
found that IFN-c~ increased the number of IFN-3,-secreting 
CD4 Th cells 10-fold within 24 h of culture, but that it did 
not regulate IFN-3' production by CD8 ceUs. Furthermore, 
IFN-c~ antagonized the suppressive effect of IL-4 on IFN-3, 
production, but did not affect the secretion of IL-4 by either 
CD4 or CD8 T cells. Based on this finding we propose that 
IFN-ol favors Thl-driven immune responses  by increasing 
IFN-3, production in the Th cell compartment. 
Materiah and Methods 
IL.4.  Recombinant human Ib4 was purified by gel filtration 
from extracts of Escherichia coli cells transfected with the human 
Ib4 gene as described dsewhere (36). The specific activity of 2.5 
x  107  U/rag  was  comparable to  preparations commercially 
available. 
IFN-ot.  Recombinant human IFN-c~ B (alpha 8; Ciba-Geigy, 
Basel, Switzerland) with a specific activity of 2.5  x  107 IU/mg 
was used in all experiments. HuIFN-c~ B was calibrated against 
the National Institutes of Health standard  G 023-901-527 of  HuIFN- 
c~ by determining plaque reduction of  vesicular stomatitis virus In- 
diana serotype on human embryonic foreskin diploid ceils (37, 38). 
T Cell Separation.  PBMC were isolated  by Ficoil-Hypaque  cen- 
trifugation (39). CD4 § or CD8 + T cells were negatively selected 
on FACS  |  (Becton Dickinson & Co., Mountain View, CA) by 
depleting cells that express either CD8 or CD4, respectively, as 
well as CD14, CD16, and CD19. The sorted populations were 
>98% pure. The antibodies  used for staining (all from Becton Dick- 
inson & Co.) were FITC-labeled Leu3a (anti-CD4), Leu2a (anti- 
CD8),  LeuM3 (anti-CD14),  Leu12 (anti-CD19),  and  Leullc 
(anti-CD16). 
Detection of Single IL,4-secreting Cells (IL-4-SC) or IFN-T-SC in 
ELISPOTAssays.  mAbs to IL-4 (8F12, 3H4) (40, 41) and IFN-y 
(23.9, 76.18) were produced inhouse. To perform ELISPOT assays, 
96-well microtiter plates (Maxisorp; Nunc, Roskilde, Denmark) 
were coated with a mixture of anti-CD3 mAb OKT3 (American 
Type Culture Center; 1/~g/ml) plus either mouse anti-human IL-4 
mAb 8F12 or mouse anti-human IFN3, mAb 23.9 (1/~g/ml). Phtes 
were blocked with 2% BSA in PBS containing 0.05% NaN3 (1 h, 
37"C, 150 gl/well). Plates were washed, and isolated cells added 
in appropriate dilutions (10  s to 103 cells/0.2 ml per weN) into the 
coated ELISPOT plates. Plates were centrifuged (3 min, 50 g) and 
incubated at 37~  for 24 h to detect IFN-~/-SC and IL-4-SC. A 
1 Abbreviations used in this paper: ELISPOT, enzyme-linked  immunospot; 
SC, secreting cells. 
longer incubation did not increase the numbers of either Ib4 or 
IFN-'y-spots. Cells were removed and developing  antibodies added 
to the plates (IL-4:  biotinqabeled  mouse anti-human Ib4 mAb 3H4, 
0.2 #g/well, 2 h, 37~  IFN-qr: biotin-labded mouse anti-human 
IFN-3, mAb 76.18, 0.2 ~g/well, 2 h, 37~  Plates were washed, 
and avidin-AP  was added (0.2 gg/well, 2 h, 370C; Zymed Labs., 
Inc.,  San  Francisco, CA).  After  additional washing,  substrate 
(bromo-4-chloro-3-indolylphospat, 0.1 #g/well; Sigma Chemical 
Co., St. Louis, MO) was added, and the development of visible 
ELISPOTS followed  microscopically.  After 30-50 rain, plates were 
rinsed with HzO and air dried. ELISPOTS were counted either 
by microscopy  or by using an automated ELISPOT  counter (ASBA, 
Basel, Switzerland). 
Detection of lFN-9, in Culture Supernatants by ELISA.  96-well 
microtiter plates (Maxisorp) were coated with mouse anti-human 
IFN-~/mAb 23.9 (1 gg/ml). All plates were blocked with 2% BSA 
in PBS containing 0.05% NaN3 (1 h, 37~  150/A/well). After 
washing with PBS, test samples or control human IFNw were added 
in blocking buffer (100 #l/well) and incubated for 16 h at room 
temperature. After washing, mouse anti-human IFN-3/mAb 76.18 
was added (0.2 #g/well, 2 h, 37~  Plates were washed and in- 
cubated with goat anti-mouse Ig coupled to alkaline  phosphatase 
(0.1 gg/weil; Tago, Inc., Burlingame, CA). Plates were washed 
and phosphatase substrate was added (0.1 mg/weil; Sigma Chem- 
ical Co.). 
PCR Analysis.  48-well  culture plates were coated for 24 h with 
anti-CD3 mAb (OKT3, 50 gg/ml) and washed. CD4 T cells (2 
x  10Vml) were added and cultured for 12-48 h in the presence 
of Ib2 (50 U/m1) and various concentrations of IFN-c~. Preacti- 
vated ceils  were lysed  with 600 #1 of guanidininm thiocyanate  buffer 
(4 M guanidinium thiocyanate,  25 mM sodium citrate, pH 7, 0.5% 
sacrosyl, 0.1 M mercaptoethanol) and the cellular KNA was iso- 
lated by two cycles of acidic phenol extractions (42). The KNA 
pellet was dissolved  in diethylpyrocarbonate-treated  water and the 
concentration was determined by measuring the OD~0 rim. The 
PCK amplifications  were performed with the Gene Amp PCR kit 
(Perkin-Elmer Cetus, Norwalk, CT) and commercially available 
primers for IFN-% and beta-Actin (Clontech, Palo Alto, CA) ac- 
cording to the manufacturer's instructions. Briefly,  100 ng of total 
RNA were reverse transcribed with 5 U of reverse transcriptase 
at 37~  for 20 rain, using as primers the specific PCK primers. 
Amplifications  were performed for 30 cycles  (1 min at 60~  1 rain 
at 72~  1 rain at 94~  using a thermal reactor from Hybaid  R, 
Middlesex, UK. The amplified  DNA was separated  on a 1% agarose 
gel together with DNA size markers. The gel was stained with 
ethidium bromide and the bands were visualized  by UV transiUu- 
mination at 366 nM. The relative intensities of the bands were de- 
termined by scanning the polaroid picture of the gel with a video 
densitometer (Bio-Rad Laboratories,  Richmond, CA) in the reflec- 
tion mode. The values  obtained  with IFNw were standardized  with 
respect to beta actin RNA levels, to correct for variations in KNA 
amount. 
Northern Blot Analysis.  10 gg of KNA from each sample was 
separated on 1% agarose/6.6% formaldehyde  gels (43) and trans- 
ferred to gene screen membranes using a posiblotter (Stratagene, 
Inc., La Jolla, CA). After baking the filters at 80~  for 2 h and 
prehybridization for 6 h, the filters were hybridized (43) with the 
labeled probes for IFN-3' and 288 ribosomal RNA for 12-16 h at 
42~  The probes were prepared using standard techniques (43). 
Labeling was carried out using the random primer technique (44). 
The filters were washed three times at 55~  in 0.1x  SSPE, 0.1% 
sodium dodecyl  sulfate  (20x SSPE = 3.6 M sodium chloride, 0.2 M 
sodium phosphate, 0.02 M EDTA, pH 7.4) and exposed to Kodak 
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were determined by scanning the autoradiograph with  a den- 
sitometer. 
Results 
Detection of  Single IL-4- and IFN-  y-secreting Cells by ELISPOT 
Assay.  Allergic immune responses in vivo depend on acti- 
vated Th2 cells that produce increased levels of IL-4 and de- 
creased levels of IFN-3, (45-48).  To determine the frequency 
of T  cells present  in the peripheral blood that are capable 
of secreting IL-4 or IFN-3' upon stimulation via the TCR/ 
CD3 complex, we developed ELISPOT assays  that allow the 
detection of single IL-4-SC and of IFN-3,-SC  within 24 h 
of culture.  CD4 or CD8 T  cells (103-10S/well) were acti- 
vated for 24 h in ELISPOT plates coated with a mixture of 
anti-CD3 mAb plus either anti-IFN-'y or anti-IL-4 mAb. This 
approach allowed simultaneous stimulation of the T cells and 
binding of the secreted lymphokine to the plate. As demon- 
strated in Fig. 1, neither IL-4- nor IFN-3,-SC  were detect- 
able, if the plates were only coated with the activating anti- 
CD3 mAb in the absence of specific mAb to IL-4 or IFN-% 
Figure  1.  Detection of single IL-4-SC or IFN-"/-SC in ELISPOT assays. 
To detect IL-4-SC or IFN-3~-SC, ELISPOT plates were coated as indicated 
with a mixture of anti-CD3 mAb OKT3 (1/~g/ml) plus either mouse 
anti-human IL-4 mAb 8F12 or mouse anti-human IFN-3~ mAb 23.9 (1 
/~g/ml). Control culture wells were coated with either anti-lb4, anti-IFN-% 
goat anti-human Ig, or anti-CD3 alone, or with a mixture of anti-CD3 
plus goat anti-human Ig, or anti-CD3 alone, or with a mixture of anti- 
CD3 plus goat anti-human Ig. Plates were blocked with BSA. Purified 
CD4 cells were added in appropriate  dilutions (10s-103 calls/0.2  ml per 
well).  Plates were incubated  at 37~  for 24 h. Cells were removed,  de- 
veloping antibodies added, and plates incubated for 2 h. (II~, biotin-labeled 
mouse anti-human IL-4 mAb 3H4, 0.2/~g; IFN-% biotin-labeled  mouse 
anti-human IFN-~/mAb 76.18, 0.2/zg). Plates were washed,  avidin-AP 
was added (0.2/~g),  and plates were incubated  for 2 h. Phosphatase sub- 
strate (bromo-4-chloro-3-indolylphospat,  0.1/~g) was added, and the de- 
velopment of  visibh ELISPOTS followed microscopically. After 30-50 min, 
plates were rinsed with H20 and air dried.  ELISPOTS were counted ei- 
ther by microscopy  or by using an automated ELISPOT counter. 
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or if the plates were coated with anti-CD3 mAb plus an ir- 
relevant antibody. In contrast, IL-4-SC (1:120) and IFNw-SC 
(1:70) were found, if plates were coated with anti-CD3 plus 
either anti-IL-4  or anti-IFN-3,  mAb, respectively. The fre- 
quency of responding cells was independent of the cell den- 
sity within concentrations between 10  s and 103 ceUs/0.2 ml 
per well. A persistent stimulation of the T cells by anti-CD3 
mAb was essential to maintain lymphokine secretion, since 
only low numbers of IFN-"/-SC  (1:10,000) and IL-4-SC 
(1:100,000) were detectable in the absence of anti-CD3 trig- 
gering. Active secretion of IFN-3~ or IL-4 was revealed by 
the addition of cycloheximide during culture, a treatment 
that  completely abolished  ELISPOT  formation (data  not 
shown). Addition of  graded amounts of  free soluble anti-IL-4 
mAb 8F12 or anti-IFN-3r mAb 23-9 during the cell culture 
inhibited, in a dose-dependent manner, the formation of  IL-4 
or IFN-3, spots, respectively (data not shown). Furthermore, 
addition of  unlabeled anti-IL-4 mAb 3H4 or anti-IFNw mAb 
76-18 after the cell incubation period prevented the develop- 
ment of spots after subsequent exposure of ELISPOT plates 
to biotinyhted anti-IL-4 mAb 3H4 or anti-IFN-3, mAb 76-18. 
Together these observations  attest  to  the high degree of 
specificity  of  this assay, and show that the applied system pro- 
vides a powerful tool to induce and to quantify potential IL-4- 
and IFN-3~-producing T  cells within 24 h in vitro. 
Frequency of IL-4- and IFN-~/-producing CD4 and CD8 T 
Cells in the Peripheral  Blood of  Healthy Individuals.  In the next 
set of experiments we determined the frequency of periph- 
eral blood T cells that immediately  respond with IL-4 and/or 
IFN-~/ production upon T  cell receptor-CD3 triggering. 
Within randomly selected healthy individuals, the frequen- 
cies of  IFN-3,-secreting  CD4  T  cells were  comparable 
(1:50-300),  whereas  the frequency of IL-4-producing cells 
varied considerably between 1:110 (Table 1) and <1:100,000 
(data not shown). The different numbers of IL-4-SC found 
in different individuals were not related to experimental  vari- 
ation. Within three independent experiments,  the numbers 
of IL-4-SC detected with CD4 T  cells from the same in- 
dividual varied between 1:110 and 1:300 (donor 1, Table 1). 
In the same donor, IFN-~/production varied in CD4 cells 
from 1:80 to 1:110, and in CD8 cells from 1:5 to 1:6. There- 
fore the ELISPOT system can be used to determine frequen- 
cies of  potential lymphokine secreting cells. However, all ex- 
periments presented were performed within a 6 mo period. 
We do not know if the frequencies may change in response 
to antigen-allergen exposure and therefore vary with the time 
of the year. 
To study the effect of IFN-c~ on IL-4 and IFN-3~ produc- 
tion, T cells of three preselected donors were used (Table 1). 
CD4 T cells of these donors secreted detectable amounts of 
IL-4 at a frequency of 1:110-8,000 and IFN-'y at frequencies 
of 1:50-110. CD8 T  cells from these donors secreted IL-4 
at frequencies  between 1:5,300 and <1:100,000, but produced 
IFN-3~ at frequencies of 1:4-8. 
IFN-c~ Increases the Number of IFN-7-producing CD4  T 
Cells.  We have recently demonstrated that IFN-ot inhibits 
the potential of T  cells to help antibody production by B 
cells by interfering with the initial T cell activation process Table  1.  Frequency  of IL-4 and IFN-y-secreting CD4 and CD8  T  Cells in the Pe@heral Blood 
Frequency  of CD4 + T  cells 
that  produce: 
Frequency  of CD8 + T 
cells that  produce: 
Exp.  Donor  IL-4  IFN-'r  IL-4  IFN-3~ 
1  1  1:110  1:80  1:5,000  1:5 
2  1  1:300  1:90  1:8,000  1:5 
3  1  1:230  1:110  1:6,200  1:6 
4  2  1:150  1:50  1:3,300  1:4 
5  3  1:8,000  1:100  <1:100,000  1:8 
CD4- or CD8-positive T cells were sorted by FACS  |  from PBMC of individuals  that had been preselected and mounted satisfactory IL-4 responses. 
Cells (103-10S/well) were cultured for 24 h with IL-2 in ELISPOT plates coated with either anti-CD3 plus anti-IL-4,  or with anti-CD3 plus anti- 
IFN-% to detect  IL-4- or IFN-3,-secreting cells, respectively.  After 24 h, cells were removed, and the lymphokine bound to the plate was detected 
as described in the legend to Fig.  1. 
(18). To determine whether IFN-c~ affects lymphokine produc- 
tion  of T  cells,  we isolated CD4 §  and  CD8 §  T  cells  by 
FACS  |  and cultured  them  (103/weU)  for 24 h  with  IL-2, 
but with  or  without  CD14  monocytes (100/well)  and/or 
IFN-a. Cultures were performed in plates coated with a mix- 
ture  of anti-CD3  and anti-IFN-~/mAb.  In  the  absence of 
IFN-ot, IFN-3' production was more frequent in CD8 cells 
(1:5)  than  in CD4 cells (1:100;  Fig.  2).  In  the presence of 
IFN-c~,  the number  of IFN-y-produdng  CD4 T  cells in- 
creased 10-fold within 24 h.  Addition of CD14 monocytes 
to the cultures had no effect. In contrast  to CD4 cells,  the 
frequency  of IFN-3,-producing  CD8  cells  (1:5)  was  not 
changed by IFN-oe. The results indicate that IFN-a increases 
IFN-3,  production  by CD4 but not by CD8 T  cells. 
IFN-cr Does  Not Increase  the Number of  lL-4-producing CD4 
Cells.  In the preceding section we have shown that IFN-cr 
increases  IFN-3r production in CD4 T cells. To test whether 
IFN-ol also affects IL-4 production, we determined the number 
of IL-4-SC under identical conditions.  As demonstrated in 
Fig. 3, IL-4 production occurred in 1:110 CD4 and in a 1:5,300 
CD8 T  cells.  IFN-cr  did not increase the frequency of IL-4 
producers within  either  the CD4  or the CD8 population. 
The results  indicate  that  IFN-o~ favors the expression of a 
Thl  phenotype by T  cells. 
The Numbers of  lFN-y-SC Are Proportional  to the Amounts 
of IFN-y Secreted Into the Culture Supernatant.  To  analyze 
whether the increased number of IFN-7-SC induced by IFN-c~ 
correlates to increased amounts  of IFN-3~ secreted into  the 
culture supernatant, we stimulated T cells as described above 
in the presence of various concentrations of IFN-c~. Cells were 
cultured at 104/0.2 ml per well to determine the number of 
IFN-3,-SC,  and  at  106/1  ml  per  well  to  determine  the 
amount of IFN-3, secreted into the culture supematant.  As 
Figure  2.  IFN-o~  increases the frequency of IFN-3/-secreting  CD4 but 
not CD8 T  cells. Culture plates were coated with anti-CD3 plus  anti- 
IFN-~/mAb. Purified  CD4 or CD8 T  cells (103/well) were added and 
cultured for 24 h with II.-2 (50 U/ml) with or without CD14 monocytes 
(100/well) in the presence or absence of IFN-~ (10 ng/ml). After 24 h, 
cells were removed, and IFN-~/spots were developed as described in the 
legend to Fig.  1. 
Figure  3.  IFN-ot does not increase the frequency of Ib4-secreting CD4 
T  cells. Culture plates were coated with anti-CD3 plus anti-IL4 mAb. 
Purified CD4 or CD8 T cells (10Vwell) were added and cultured for 24 h 
with IL-2 (50 U/ml) with or without CD14 monocytes  (103/we11) in the 
presence or absence of IFN-~ (10 ng/ml). After 24 h, cells were removed, 
and the Ib4 spots were developed as described  in the legend to Fig.  1. 
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Figure 4.  Correlation  between the number of IFN-7-SC and the 
amount of secreted IFN-% To determine  the numbers  of  IFN-7-SC, cul- 
ture plates  were  coated  with anti-CD3  plus  anti-IFN-3,  mAb. Purified  CD4 
T cells (104/well) were added and cultured  for 24 h with Ib2 (50 U/ml) 
in the presence of increasing concentrations  of IFN-r~. After 24 h, cells 
were removed,  and IFN-',/spots  were  developed  as described  in the legend 
to Fig. 1. To determine  the amounts  of IFN-7 secreted into the culture 
supernatant, CD4 T cells (106/ml) were cultured in IL-2 (50 U/ml) in 
the presence of increasing concentrations  of IFN-a. After 24 h, culture 
supernatants were harvested and analyzed  for IFN-~/by ELISA. 
shown in Fig. 4, IFN-a increased the numbers of IFN-7-SC 
and the amounts of IFN-3' secreted into the culture superna- 
tant '~10-fold and in a dose-dependent fashion. Single cells 
secreted  ~0.4 pg/24 h  of IFN-3, independent of the pres- 
ence or absence of IFN-c~. This indicates that IFN-c~ increases 
the frequency of IFN-3,-SC rather than increasing the rate 
of IFN-'y production per single cell. 
IFN-oe Increases the Expression of IFN-'f mRNA.  In the 
preceding  experiment  we  have  demonstrated that  IFN-ot 
specifically promotes the secretion of IFN-'y but not of IL-4 
by CD4 T  ceils. To analyze whether IFN-a induces IPN-'y 
gene expression, we stimulated CD4 T cells by plate-bound 
anti-CD3 mAb in the presence  or absence  of IFN-ot, and 
determined mRNA for IFN-3, by PCR (42) after 12-48 h 
(Fig. 5 A). We found that anti-CD3 triggering induced ex- 
pression of IFN-3~ mRNA,  and addition of IFN-a to the 
cultures prolonged the expression of IFN-3, message. Quan- 
tification of IFN-3/mRNA by Northern Blot analysis re- 
vealed that about three- to fourfold higher amounts of  IFN-~/ 
mRNA were present after 24 h stimulation in the presence 
of IFN-a (Fig.  5 B). The results may indicate that IFN-a 
increases-stabilizes  the expression of IFN-3, mRNA in CD4 
T  cells. 
IFN-at  Antagonizes the Suppressive  Effect  of  lL-4 on the Secretion 
oflFN-%  It has recently been demonstrated that IL-4 sup- 
presses the production of IFN-3' by PBMC (49, 50). To ana- 
lyze whether IPN-c~ could antagonize the suppressive activity 
of IL-4, we stimulated CD4 T  cells  (106/ml)  for 24-72  h 
by plate-bound anti-CD3 mAb in the presence of either IL-4 
or IFN-a, or in the presence of IL-4 plus IFN-c~. In the ab- 
sence of exogenously added lymphokines, 4 ng of IFN-y was 
produced within 72 h of culture (Fig. 6). Addition of IL-4 
reduced IFN-3~  production to 1 ng, whereas addition of IFN-a 
increased IFN-3' production to 10 ng. In the presence of IL-4 
plus IFN-a, the levels of secreted  IFN-3' were comparable 
to those observed in the presence of IFN-a alone. This demon- 
strates  that IFN-a completely antagonizes the suppressive 
effect of IL-4 on IFN-3~ secretion by CD4 T ceUs. We specu- 
late that IFN-a may favor the generation of Thl-like cells 
by inducing IFN-7 and by antagonizing the suppressive effect 
of IL-4 on IFN-3~ production. 
IFN-cr  Increases IFN-y  Production by  Allostimulated  T 
Cells,  In the preceding section we have shown that IFN-a 
critically increases the production of IFN-3, in CD4 T  cells 
stimulated by plate-bound anti-CD3 mAb. To further prove 
the physiological relevance of the finding, we analyzed the 
effect  of IFN-a in mixed lymphocyte culture.  Therefore, 
PBMC of two different donors (2  x  106/ml) were cultured 
in the presence of increasing concentrations of IFN-a either 
separately  without TCR triggering, or together to induce 
allostimulation.  Culture supematants were harvested after 24 h 
and analyzed for IFN~ by ELISA. Without allostimulation, 
IFN-a did not increase IFN-3' production significantly (Fig. 
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Figure  5.  IFN-,v increases the 
expression of mRNA for IFN-% 
CD4 T cells (2  x  106/ml) were 
stimulated  by  phte-bound  anti-CD3 
antibody  in the presence oflb2 (50 
U/ml) with or without IPN-a (10 
ng/ml)  as indicated.  After  12-48 h, 
ceUs were  harvested  and mRNA  was 
detected by PCR (A) (representa- 
tive  of three  experiments  with three 
different donors). Furthermore, 
mRNA was quantified  after 24 h 
by Northern  Blot  analysis  (/3) (lane 
1, no IFN-a; lane 2), IFN-a 10 
ng/ml). The relative  intensities of 
the bands were  determined  by scan- 
ning the polaroid  picture  of the gel 
with a video densitometer. Figure 6.  IFN-c~  antagonizes the suppressive  effect oflL-4 on the produc- 
tion of IFN-3'. CD4 T cells (l(P/ml) were cultured for 3 d in anti-CD3 
coated plates with either  Ib4 (50 ng/ml)  or IFN-ot (10 ng/ml) alone, or 
with Ib4 plus IFN<x. Culture  supernatants  were  harvested  after  24, 48, 
and 72 h, and analyzed  for IFN-3' by ELISA (means of duplicates). 
7). In contrast,  IFN-ol increased the production of IFN-'y 
in a dose-dependent fashion, and up to sixfold within 24 h 
in mixed leukocyte cultures.  The results may indicate that 
stimulation of IFN-'y production by IFN-oL represents a phys- 
iological mechanism to favor the development  of Thl-like 
cells in vivo. 
Discusa/on 
In this  study we have determined the relative frequency 
of potential  IL-4- and IFN-~-producing T cells present in 
the peripheral blood of healthy individuals, and analyzed the 
effect of IFN-a on the secretion of  IFN-~/and IL-4. To mini- 
mize effects of endogenously produced lymphokines and 
cell-cell  interactions  in  vitro,  highly purified  CD4 §  and 
CD8 §  T  cells were stimulated  by plate-bound  anti-CD3 
mAb at low cell density and in the absence of accessory cells, 
and lymphokine secretion was accessed  during the initial 24 h 
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Figure  7.  IFN-o~  increases 
IFN-3' production  by allostimu- 
lated PBMC. PBMC of  two 
donors (106/ml) were cultured 
separately  (O and []), or were  al- 
lostimulated in MLC (106 plus 
106/ml; e) in the presence of 
IFN-<x as indicated. Culture su- 
pernatants were analyzed for 
IFN-'y after 24  h  (means of 
duplicates). 
of culture.  Within randomly selected normal individuals, 
IFN-'y was produced by 1:50-300 CD4 cells and by 1:5-10 
CD8 cells. The number of IL-4-SC ranged from undetect- 
able levels to 1:110 in CD4 cells and to 1:5,300 in CD8 cells. 
Since it has been found that IFN-'y inhibits the clonal expan- 
sion of  Th2-1ike cells in response to antigen (51), the relative 
constant number of IFN-'),-SC found in different healthy in- 
dividuals may strictly control Th2-like cells and thereby coun- 
teract excessive IL-4 production. We do not favor a direct 
action of IFN-'y on the expression of the IL-4 gene, since 
exogenously added IFN-'y neither increased nor decreased the 
frequency of IL-4-SC (data not shown). 
The signals inducing the production of  either IL-4 or IFN-3~ 
in T  cells remain largely unknown. It has been suggested 
that unique cofactors are necessary for optimal stimulation 
of Thl and Th2 clones, and that different cofactors may be 
produced by different antigen-presenting  cells. It was found 
that B cells presenting OVA stimulated optimal proliferation 
of Th2 clones, whereas  adherent  cells stimulated  optimal 
proliferation of  Thl cells (52). Since antigen-presenting mac- 
rophages but not B cells produce large amounts of IFN-oL 
(53) and stimulate  Thl clones (52), we analyzed whether 
IFN-o~ would favor the expression of a Thl phenotype in 
T  cells. We found that IFN-c~ increased the expression of 
mRNA  for  IFN-3'  and  as  a  consequence  the  frequency 
of  IFN-'g-producing  CD4 T cells and the amounts of  secreted 
IFN-'y. In contrast,  IFN-ol did not increase the frequency 
of IFN-3,-producing CD8 T cells. The fact that similar results 
were obtained with anti-CD3 or allostimulated T cells may 
point to the physiologic relevance of the immunomodula- 
tory mechanism.  The results strongly suggest that IFN-o~ 
favors the generation of IFN-3,-producing Thl-like cells. It 
is reasonable that, given the capacity of viruses and intracel- 
lular bacteria to stimulate macrophage production of IFN-ol 
(53), Th cells may be simultaneously presented with processed 
antigen and IFN-c~, which induces them to differentiate to- 
wards a Thl-like phenotype. It might be speculated that al- 
lergens inducing Th2 rather than Thl cells (29) may be poor 
stimulators  of IFN-ol production by macrophages, or may 
rather be presented by APC, which do not produce IFN-c~. 
Therefore, desensitization of allergic patients with allergen 
in combination with Th2-suppressive agents like IFN-ol could 
induce allergen-specific  Thl- rather than Th2-like cells  in vivo. 
It is likely that an allergen-specific Thl memory would pro- 
tect against future allergic reactions, since  the increased levels 
of IFN-'y and the decreased levels of IL-4 produced by Thl 
cells would reduce the clonal expansion of Th2 cells (51) as 
well as the switch of B cells to IgE (15, 19). 
The described mode of action may also explain the beneficial 
effects of IFN-o~ in the treatment of HIV infection (7, 8). 
It has been discussed that the progression to AIDS is charac- 
terized by loss of IL-2 and IFN-qr production and increases 
in IL-4 and IL-10 (54). In contrast, many seronegative, HIV- 
exposed individuals  generate strong Thl-type responses to 
HIV antigens. It is tempting to speculate that protective Thl 
responses to HIV antigens may prevent seroconversion and 
the development of AIDS even after multiple exposures to 
HIV (54). Interestingly,  HIV infection of monocytes-mac- 
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From our data it may be conduded that the presentation of 
HIV to T cells by IFN-ot-deficient macrophages would favor 
the development of HIV-specific Th2-1ike cells.  Therefore, 
the progression of HIV infection to AIDS may at least be 
delayed with drugs like IFN-c~ that stabilize Thl responses. 
Future vaccine protocols could aim on the specific induction 
of Thl immune responses through vaccination with a cock- 
tail of antigen  plus agents like IFN-cr  anti-IL-4  mAb,  or 
soluble IL-4 receptor. 
In our system, IFN-c~ increased the production of IFN-3, 
but not of IL-4 by CD4 T cells. However, it has been demon- 
strated in mice that IFN-ot treatment during immunization 
with foreign anti-IgD  antibodies reduces message for IL-4 
and increases message for IFN-'/in total splenic T cells (17). 
In the light of our data, IFN-~ may not deactivate the IL-4 
gene, but may rather increase the relative number of IFN- 
y-producing cells in the spleen by activating the IFN-3' gene 
in the CD4 Th helper cell compartment.  The increased ex- 
pression of IFN-3' would inhibit proliferation of Th2- but 
not of Thl-like cells (51), and thereby indirectly control the 
expression of IL-4. The profound effect of IFN-c~ on IFN-3, 
production by Th cells may also explain its suppressive effect 
on IgE production in vitro (15) as well as in vivo (13,  16, 
17). It is unlikely that IFN-c~ displays a direct effect on the 
B cell level, since it does not block the IgE switch in human 
B cells that are stimulated by preactivated helper cells in the 
absence of IFN-3, and in the presence of exogenously added 
IL-2 and IL-4 (18). 
Recently it has been described that a 15-kD protein that 
induces IFN-3, production is released by human monocytes 
and lymphocytes after IFN-ot treatment (56). However, this 
protein should induce IFN-3, production in both CD4 and 
CD8 T  cells,  which was not observed (56).  In our hands, 
IFN-ot only acted on CD4 T  cells,  and addition of mono- 
cytes to purified CD4 or CD8 T cells did not alter their re- 
sponsiveness to IFN-ot. 
From  the data we conclude that  IFN-ot,  which can be 
released in large amounts by antigen-presenting macrophages 
(52, 53), may favor the generation of THl-like ceils by ac- 
tivating  the  gene  for  IFN-3,  in  CD4  T  cells,  and by an- 
tagonizing the suppressive effect of IL-4 on IFN-3, produc- 
tion by these cells.  The described mechanism  may explain 
the beneficial effects of IFN-a  in the treatment  of allergic 
disease situations (13, 14) and of HIV infections (7, 8). These 
diseases are, at least at certain stages, characterized by a defective 
production of IFN-3, and/or an increased production of IL-4 
(29,  47,  54,  57). 
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